|
|
|
|
|
|
|
M T W Th Fri |
|
29 May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Executive Editor Drew Armstrong is out with a piece today about Eli Lilly's decision to no longer disclose Phase 1 projects. As Drew writes, "it’s a shame that one of the pharma industry’s most influential companies now shares less about its science and business." |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Zachary Brennan
|
The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the... | |
|
|
|
 |
|
|
|
by Drew Armstrong
|
Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects... | |
|
|
|
|
|
|
|
|
by Max Bayer
|
Third time’s the charm? Replimune announced Fridaythat it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
🔎 AstraZeneca narrows path for failed antibody: The company announced last summerthat its monoclonal antibody anselamimab missed the primary endpoint in a pair of... | |
|
|
|
 |
|
|
|
by Alex Hoffman, Lei Lei Wu, Kyle LaHucik
|
Longtime Allogene CEO David Chang will be stepping downat the end of June. Chang has served as the company’s CEO for the past eight... | |
|
|
|
|
|
|
by Lei Lei Wu
|
Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of... | |
|
|
|
